Notícias Eulerpool Ascletis Pharma

Ascletis Pharma Eulerpool-AFX

Ascletis Pharma Notícias de ações

Ascletis Pharma é observado por muitos jornalistas e investidores em todo o mundo. As notícias mais recentes de Ascletis Pharma nós reunimos aqui.

• 11 de junho ·

  Yahoo
  Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
• 3 de abril ·

  Yahoo
  Ascletis Announces Strategic Decisions on FXR agonist ASC42
• 11 de março ·

  Yahoo
  Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
• 28 de janeiro ·

  SeekingAlpha
  Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
• 24 de janeiro ·

  Yahoo
  Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
• 23 de janeiro ·

  Yahoo
  Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
• 2 de janeiro ·

  Yahoo
  Gannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic Steatohepatitis
• 5 de dezembro ·

  Yahoo
  Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
• 13 de novembro ·

  Yahoo
  Ascletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHB
• 9 de novembro ·

  Yahoo
  Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023